InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: 1center post# 319

Saturday, 09/10/2016 2:14:41 PM

Saturday, September 10, 2016 2:14:41 PM

Post# of 1162

$BMY is most likely being watched and will find support.



I would disagree. Have you noticed that IIs are dumping Bristol Myers Squibb as BlackRock has decreased positions and Kennedy Capital Management...etc

I may have found another puzzle piece why Bristol Myers Squibb is being sold off and funds are exiting or atleast decreasing their positions and leveraging with other small biotechs ...

The key to Opdivo was Dr. Jedd Wolchok and I noticed he is missing from this latest research on IO combo therapy

-------------------------------------------------------

Published: September 9, 2016

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology


Mark J. Selby,
John J. Engelhardt,
Robert J. Johnston,
Li-Sheng Lu,
Minhua Han,
Kent Thudium,
Dapeng Yao,
Michael Quigley,
Jose Valle,
Changyu Wang,
Bing Chen,
Pina M. Cardarelli,
Diann Blanset,
Alan J. Korman

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161779



-----------------------------------------------------------

Obviously, some should dig deeper and find out where Dr. Jedd Wolchok is at on his research and I may have found the answer to that as well...

Dr. Jedd Wolchok began working with "PS Targeting" back in May 2015 and he will be at SITC this November 2016 so it will be interesting to find out what is being learned in his lab and beyond.

Maybe Bristol Myers Squibb realized that Opdivo only is effective on 20-35% of patients and if Dr. Jedd Wolchok is missing for IO combo therapy for Opdivo ?? Then..... he must be on to bigger and better things...

Opdivo works in only ~20-35% of NSCLC Patients, those that express PD-L1 > 10%. In BMY’s Checkmate-057 NSCLC trial, Opdivo DID NOT increase survival vs. DOCE in the 64% of All Pts that didn’t express PD-L1 > 10% (see BMY’s K-M Charts below). Thus, the window of opportunity for Bavi is essentially 2/3+ of the NSCLC market.

http://investorshub.advfn.com/BOARDS/read_msg.aspx?message_id=117419956


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News